高流量鼻导管氧疗与标准氧疗对急性呼吸衰竭免疫功能受损患者28天死亡率的影响:HIGH随机临床试验
HIGH随机临床试验在法国32个ICU纳入776例免疫功能受损的急性低氧性呼吸衰竭成人患者,随机1:1接受连续高流量鼻导管氧疗(n=388)或标准氧疗(n=388)。主要终点28天死亡率两组无显著差异(35.6% vs 36.1%;差异-0.5%[95%CI -7.3%至+6.3%];HR 0.98[95%CI 0.77至1.24];P=.94)。插管率亦无显著差异(38.7% vs 43.8%;差异-5.1%[95%CI -12.3%至+2.0%])。高流量组在6小时后PaO2:FIO2较高(150 vs 119;差异19.5[95%CI 4.4至34.6])、呼吸频率较低(25/min vs 26/min;差异-1.8/min[95%CI -3.2至-0.2]),但ICU住院时间、ICU获得性感染、医院住院时间及患者舒适度和呼吸困难评分无显著差异。
要点
- 免疫功能受损的急性低氧性呼吸衰竭成人患者中,高流量鼻导管氧疗组28天死亡率为35.6%,标准氧疗组为36.1%,差异无统计学显著(HR 0.98[95%CI 0.77至1.24];P=.94)。
- 插管率两组无显著差异:高流量组38.7% vs 标准氧疗组43.8%(差异-5.1%[95%CI -12.3%至+2.0%])。
- 高流量组6小时后PaO2:FIO2为150,标准氧疗组为119,差异19.5(95%CI 4.4至34.6)。
- 高流量组6小时后呼吸频率为25/min,标准氧疗组为26/min,差异-1.8/min(95%CI -3.2至-0.2)。
- ICU住院时间、ICU获得性感染、医院住院时间及患者舒适度和呼吸困难评分两组均无显著差异。
适用人群与场景
- 成人免疫功能受损的急性低氧性呼吸衰竭患者,需满足PaO2<60 mmHg或室内空气下SpO2<90%,或呼吸急促>30次/分或呼吸困难或呼吸窘迫,且需要氧疗≥6 L/min。
- 研究在法国32个ICU进行,纳入时间为2016年5月19日至2017年12月31日。
诊断标准与关键阈值
- 急性低氧性呼吸衰竭定义:PaO2<60 mmHg或室内空气下SpO2<90%,或呼吸急促>30次/分或呼吸困难或呼吸窘迫,且需要氧疗≥6 L/min。
处置流程与药物剂量
- 高流量鼻导管氧疗组(n=388)接受连续高流量氧疗;标准氧疗组(n=388)接受标准氧疗。
研究设计与关键结果
- 研究类型:随机临床试验(HIGH),在法国32个ICU进行,纳入776例成人免疫功能受损的急性低氧性呼吸衰竭患者,随机1:1接受连续高流量鼻导管氧疗(n=388)或标准氧疗(n=388)。
- 主要终点28天死亡率:高流量组35.6% vs 标准氧疗组36.1%;差异-0.5%(95%CI -7.3%至+6.3%);HR 0.98(95%CI 0.77至1.24);P=.94,无显著差异。
- 插管率:高流量组38.7% vs 标准氧疗组43.8%;差异-5.1%(95%CI -12.3%至+2.0%),无显著差异。
- 6小时后PaO2:FIO2:高流量组150 vs 标准氧疗组119;差异19.5(95%CI 4.4至34.6)。
- 6小时后呼吸频率:高流量组25/min vs 标准氧疗组26/min;差异-1.8/min(95%CI -3.2至-0.2)。
- ICU住院时间:高流量组8天 vs 标准氧疗组6天;差异0.6天(95%CI -1.0至+2.2),无显著差异。
- ICU获得性感染:高流量组10.0% vs 标准氧疗组10.6%;差异-0.6%(95%CI -4.6至+4.1),无显著差异。
- 医院住院时间:高流量组24天 vs 标准氧疗组27天;差异-2天(95%CI -7.3至+3.3),无显著差异。患者舒适度和呼吸困难评分无显著差异。
证据类型、等级与局限
- 证据类型:随机临床试验。
- 局限:原文未报告局限性。
对床旁实践的改变
- 在免疫功能受损的急性低氧性呼吸衰竭成人ICU患者中,高流量鼻导管氧疗与标准氧疗相比未显著降低28天死亡率,两者在插管率、ICU住院时间、ICU获得性感染、医院住院时间及患者舒适度和呼吸困难评分方面亦无显著差异。
指南或共识出处
- HIGH随机临床试验,ClinicalTrials.gov注册号NCT02739451,发表于JAMA。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: High-flow nasal oxygen therapy is increasingly used for acute hypoxemic respiratory failure (AHRF).
OBJECTIVE: To determine whether high-flow oxygen therapy decreases mortality among immunocompromised patients with AHRF compared with standard oxygen therapy.
DESIGN, SETTING, AND PARTICIPANTS: The HIGH randomized clinical trial enrolled 776 adult immunocompromised patients with AHRF (Pao2 <60 mm Hg or Spo2 <90% on room air, or tachypnea >30/min or labored breathing or respiratory distress, and need for oxygen ≥6 L/min) at 32 intensive care units (ICUs) in France between May 19, 2016, and December 31, 2017.
INTERVENTIONS: Patients were randomized 1:1 to continuous high-flow oxygen therapy (n = 388) or to standard oxygen therapy (n = 388).
MAIN OUTCOMES AND MEASURES: The primary outcome was day-28 mortality. Secondary outcomes included intubation and mechanical ventilation by day 28, Pao2:Fio2 ratio over the 3 days after intubation, respiratory rate, ICU and hospital lengths of stay, ICU-acquired infections, and patient comfort and dyspnea.
RESULTS: Of 778 randomized patients (median age, 64 [IQR, 54-71] years; 259 [33.3%] women), 776 (99.7%) completed the trial. At randomization, median respiratory rate was 33/min (IQR, 28-39) vs 32 (IQR, 27-38) and Pao2:Fio2 was 136 (IQR, 96-187) vs 128 (IQR, 92-164) in the intervention and control groups, respectively. Median SOFA score was 6 (IQR, 4-8) in both groups. Mortality on day 28 was not significantly different between groups (35.6% vs 36.1%; difference, -0.5% [95% CI, -7.3% to +6.3%]; hazard ratio, 0.98 [95% CI, 0.77 to 1.24]; P = .94). Intubation rate was not significantly different between groups (38.7% vs 43.8%; difference, -5.1% [95% CI, -12.3% to +2.0%]). Compared with controls, patients randomized to high-flow oxygen therapy had a higher Pao2:Fio2 (150 vs 119; difference, 19.5 [95% CI, 4.4 to 34.6]) and lower respiratory rate after 6 hours (25/min vs 26/min; difference, -1.8/min [95% CI, -3.2 to -0.2]). No significant difference was observed in ICU length of stay (8 vs 6 days; difference, 0.6 [95% CI, -1.0 to +2.2]), ICU-acquired infections (10.0% vs 10.6%; difference, -0.6% [95% CI, -4.6 to +4.1]), hospital length of stay (24 vs 27 days; difference, -2 days [95% CI, -7.3 to +3.3]), or patient comfort and dyspnea scores.
CONCLUSIONS AND RELEVANCE: Among critically ill immunocompromised patients with acute respiratory failure, high-flow oxygen therapy did not significantly decrease day-28 mortality compared with standard oxygen therapy.
TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT02739451.
参考来源
- Azoulay E, Lemiale V, Mokart D, et al. Effect of High-Flow Nasal Oxygen vs Standard Oxygen on 28-Day Mortality in Immunocompromised Patients With Acute Respiratory Failure: The HIGH Randomized Clinical Trial. JAMA. 2018. PMID: 30357270. doi:10.1001/jama.2018.14282
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。